An update on treatment advances for the first-line therapy of metastatic colorectal cancer

Cancer Journal

Volumn 13, Issue 5, 2007, Pages 276-281

  Lee, James J ^a   Chu, Edward ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Colorectal; First line; Metastic

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CELECOXIB; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; VASCULOTROPIN; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ALOPECIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; TREATMENT RESPONSE; TUMOR GROWTH; COLORECTAL TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; EPIDERMAL GROWTH FACTOR; HUMANS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38449099720     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181570062     Document Type: Review

References (27)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-487.
3. Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82:114-129.
4. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
6. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-237.
7. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Me-ridionale. J Clin Oncol. 2005;23:4866-4875.
8. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/ 5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol. 2006;24(18 suppl):3509.
9. Porschen R, Arkenau H, Kubicka S, et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer - a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007; July 11 (Epub ahead of print).
10. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2007;25(18 suppl):4030.
11. Saltz L, Clarke S, Diaz-Rubio E, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2007;25(18 suppl):4028.
12. Ducreux M, Bennouna J, Hebbar M, et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O)b (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2007:25(18 suppl):4029.
13. Maughan TS, James RD, Kerr DJ, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet. 2003;361:457-464.
14. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006;24:394-400.
15. Maindrault-Goebel F, Lledo G, Chibaudel B, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. Proc Am Soc Clin Oncol. 2007;25(18 suppl):4013.
16. Collins TS, Hurwitz HI. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Semin Oncol. 2005;32:61-68.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
18. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;24:3697-3705.
19. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. Proc Am Soc Clin Oncol. 2006;24(18 suppl): 3510.
20. Fuchs C, Philip J, Mitchell E, et al. Updated results of BICC-C study comparing firsr-line irinotecan/fluoropyrimidine combinations with or without celecoxib in mCRC: updated efficacy data. Proc Am Soc Clin Oncol. 2007;25:4027.
21. Kopetz S, Glover KY, Eng C, et al. Phase II study of infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2007;25:4089.
22. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787-2799.
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
24. Díaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. Proc Am Soc Clin Oncol. 2005;23:3535.
25. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Proc Am Soc Clin Oncol. 2007;25:4000.
26. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658-1664.
27. Berlin J, Posey J, Tchekmedvian S, et al. Panitumumab with irinotecan/ leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2007;6:427-432.